Tesa10 + ip5
Tesa10 + IP5 combines two growth hormone secretagogues with distinct mechanisms of action in a single research formulation. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates GH secretion through activation of GHRH receptors on pituitary somatotroph cells, while Ipamorelin is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Because these peptides target separate receptor systems involved in regulating endogenous growth hormone secretion, they represent complementary pharmacological approaches for investigating GH-axis signalling.
Tesa10 + ip5
Sale!7%
Tesa10 + IP5 combines two growth hormone secretagogues with distinct mechanisms of action in a single research formulation. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates GH secretion through activation of GHRH receptors on pituitary somatotroph cells, while Ipamorelin is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Because these peptides target separate receptor systems involved in regulating endogenous growth hormone secretion, they represent complementary pharmacological approaches for investigating GH-axis signalling.
$169.00
Buy more, save more!
-
Save 1%
Buy 3, get $2.50 off each
$169.00Per item: $166.50Total price: $499.50 -
Save 2%
Buy 5, get $3.75 off each
$169.00Per item: $165.25Total price: $826.25 -
Save 4%
Buy 10, get $7.50 off each
$169.00Per item: $161.50Total price: $1,615.00
$182.00$169.00
99+% PURITY
All peptides are third-party lab tested.
SECURE PAYMENT
Your payments are secure with our private security network.
FREE SHIPPING
for orders over $250
Description
Additional information
Reviews (0)
Tesa + IPA Blend 10/5MG combines Tesamorelin and Ipamorelin, two growth hormone secretagogues that stimulate endogenous growth hormone release through distinct receptor pathways.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that activates GHRH receptors on pituitary somatotroph cells. At the same time, Ipamorelin is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a).
This formulation enables researchers to examine the pharmacological actions of GHRH receptor activation and GHS-R1a agonism within a single experimental framework. Although Tesamorelin and Ipamorelin have each been extensively characterized in preclinical and clinical studies, published research evaluating their combined administration remains limited.
The blend is best regarded as a research tool for studying growth hormone physiology, endocrine signalling, and related metabolic processes rather than a formulation with established therapeutic applications.
| Strength Variation |
|---|
There are no reviews yet.